Peripherally Inserted Central Catheter (PICC) Market
Peripherally Inserted Central Catheter (PICC) Market Overview 2025 to 2035
The global peripherally inserted central catheter (PICC) market is projected to reach USD 1,138.0 million in 2025 and is expected to surge past USD 1,490.8 million by 2035 at an impressive CAGR of 3.2%. The growing prevalence of chronic diseases such as cancer, cardiovascular disorders, and renal diseases, along with increasing hospital admissions, is fueling market expansion.
PICC catheters provide minimally invasive access for intravenous therapy, chemotherapy, parenteral nutrition, and blood transfusion, making them a preferred alternative to traditional central venous catheters.
Market Dynamics
Key Market Drivers
- Rising Chronic Disease Cases: The increasing prevalence of cancer, diabetes, and cardiovascular diseases is driving the demand for long-term intravenous therapies.
- Advancements in PICC Technology: The introduction of power-injected PICCs, antimicrobial-coated catheters, and bioresorbable materials enhances patient safety and procedural efficiency.
- Increasing Preference for Home Healthcare: Home-based intravenous therapies for conditions such as cancer, infections, and nutritional deficiencies are reducing hospital stays, creating new growth opportunities.
- Favorable Reimbursement Policies: Government healthcare support and insurance coverage in key markets such as the U.S., Germany, and Japan are expanding the adoption of PICC devices.
Market Restraints
- Risk of Bloodstream Infections (CRBSIs): Although safer than conventional central venous catheters, PICCs still pose infection risks, limiting adoption.
- Regulatory Challenges: Strict guidelines such as MAGIC (Michigan Appropriateness Guide for Intravenous Catheters) impact the usage of PICCs in specific medical settings.
- High Cost of Advanced PICCs: The price of newer antimicrobial and power-injected catheters may hinder affordability in developing markets.
Market Trends & Opportunities
1. Growing Demand for Antimicrobial PICCs
Hospitals and clinics are increasingly using antimicrobial-coated PICCs to reduce catheter-related infections, boosting the demand for advanced catheter materials.
2. Power-Injected PICCs Gaining Popularity
The power-injected PICC segment dominates due to its ability to administer contrast media for CT scans, making it highly preferred in radiology and oncology treatments.
3. Expansion in Emerging Markets
Countries like China, India, and Brazil are experiencing rising demand for PICC procedures due to improving healthcare infrastructure and government initiatives.
Market Segmentation
| Segment |
Sub-Segment |
|---|---|
|
By Product |
Conventional PICC, Power-Injected PICC, Neonatal PICC |
|
By Lumen |
Single Lumen, Double Lumen, Multiple Lumen |
|
By Application |
Chemotherapy, Long-Term IV Infusion, Parenteral Nutrition, Blood Transfusion, Difficult Intravenous Access |
|
By End User |
Hospitals, Cancer Research Institutes, Long-Term Care Centers, Independent Infusion Centers, Home Care Settings |
|
By Region |
North America, Latin America, Europe, East Asia, South Asia, Oceania, Middle East & Africa |
Regional Market Insights
United States: Market Leader with Technological Advancements
- Market Size (2035): USD 598.2 million
- CAGR (2025-2035): 2.2%
- Key Growth Factors: High cancer prevalence, advanced hospital infrastructure, and robust reimbursement support.
China: Rapid Market Expansion Due to Growing Aging Population
- Market Size (2035): US$ 110.5 million
- CAGR (2025-2035): 5.8%
- Key Growth Factors: Rising geriatric population, increasing chronic disease cases, and government healthcare initiatives.
Germany: Strong Adoption in Cancer Treatment
- Market Size (2035): US$ 89.3 million
- CAGR (2025-2035): 3.5%
- Key Growth Factors: High investments in cancer care, preference for antimicrobial-coated PICCs, and advanced hospital facilities.
Competitive Landscape & Key Players
| Company |
Key Developments |
|---|---|
|
Teleflex Incorporated | Launched Arrow® VPS Rhythm® DLX Device for PICC placement. |
|
Becton, Dickinson and Company | Introduced antimicrobial-coated PICCs to reduce infection risks. |
|
Cardinal Health, Inc. | Expanded its home infusion therapy solutions with PICC-based IV treatments. |
|
ICU Medical, Inc. | Developing bioresorbable catheter technology for better vascular compatibility. |
Competitive Strategies
- Product Innovation: Leading manufacturers are investing in next-gen catheter materials, bioresorbable PICCs, and power-injection capabilities.
- Mergers & Acquisitions: Companies are acquiring regional PICC manufacturers to strengthen market position.
- Market Expansion: Firms are expanding operations in emerging economies to tap into growing demand.
📢 Contact our advisory team to learn more about key players and market competition.
Frequently Asked Questions (FAQs)
1. What is the projected growth of the PICC market?
- The market is forecast to grow at 3.2% CAGR, reaching USD 1,490.8 million by 2035.
2. Why are PICCs preferred over conventional central venous catheters?
- PICCs offer minimally invasive placement, lower infection risks, and long-term IV access, making them ideal for chemotherapy and parenteral nutrition.
3. Which region is experiencing the fastest growth?
- China is leading the growth with a 5.8% CAGR due to rising chronic disease prevalence and healthcare advancements.
4. What are the latest trends in PICC technology?
- Power-injected PICCs, bioresorbable catheters, and AI-assisted PICC placement technologies are trending in the market.
Conclusion: Take Action Now!
The peripherally inserted central catheter market is expanding rapidly, driven by technological innovations, increasing chronic disease cases, and rising healthcare investments.
📢 Contact us today to access the full market report and propel your business forward with actionable insights!